Indeed, the global oncology community trusts ESMO to disseminate the latest results of cancer research. Why? Because it is ...

Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to ...

Patients with intermediate-stage liver cancer may benefit from receiving a Lenvima-Keytruda combination with transarterial ...

The results were published through poster presentation at the 2024 European Society for Medical Oncology (ESMO 2024 ... treatment simplifies clinical procedure by eliminating the need for ...

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, will be presenting multiple posters at the European Society for Medical ...

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on liver-directed cancer therapies, today announced the presentation of new subgroup analysis data from the FOCUS Phase ...

ORRs of 54.8% and 50.0% achieved in locally advanced and metastatic cSCC, with median follow-up durations of 24.1 and 29.3 months, respectively. Results demonstrate a deepening of response over time, ...

These data are being presented today at the 2024 European Society for Medical Oncology Congress (ESMO 2024) during the Proffered Paper ... prior to scheduled dental surgery or invasive dental ...

ImmVira announced the latest clinical results for its lead oncolytic virus product, MVR-T3011, via intravesical ...

The ESMO Congress is a globally influential oncology ... SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.